Roivant Sciences-2026-JPM.pdf

1、J.P.Morgan Healthcare ConferenceJanuary 12,2026If You Didnt Buy Roivant in 2025,Now Is the TimeFor investor audiences onlyForward-Looking StatementsThis presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ

2、materially from those expressed or implied by such statements.All statements other than statements of historical facts contained in this presentation,including statements regarding our future results of operations and financial position,business strategy,potential uses of cash and capital allocation

3、,research and development plans,profitability,the anticipated timing,costs,design,conduct and results of our ongoing and planned preclinical studies and clinical trials for our product candidates and any commercial potential of our product candidates are forward-looking statements.These forward-look

4、ing statements are based upon our current expectations and beliefs as of the date of this presentation and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.Although we believe that our plans,int

5、entions,expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable,we can give no assurance that the plans,intentions,expectations or strategies will be attained or achieved.Furthermore,actual results may differ materially from those described in the

6、forward-looking statements.These forward-looking statements may be affected by a number of risks,uncertainties and assumptions,including,but not limited to,those risks set forth in the sections captioned“Risk Factors”and“Forward-Looking Statements”of our filings with the U.S.Securities and Exchange